drugset / Trial / NCT00376311

Effects of Oral Salmon Calcitonin in Human Osteoarthritis

NCT00376311

Phase 2 Terminated 54 enrolled Catholic University of Louvain Novartis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety, tolerability and clinical efficacy of oral salmon calcitonin in patients suffering from osteoarthritis

Timeline

Start
2002-09
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject salmon calcitonin Unknown 0.5 mg Oral
Subject salmon calcitonin Unknown 1 mg Oral

Indications